In the pursuit of predictability, we believe the best way to protect pharmaceuticals is with our people, solutions, and partners across the world.
Envirotainer has a strong focus on Asia, which is perhaps the most innovative region for pharmaceutical production at present. To serve our partners, clients an...
Anything is possible when everyone works together which was proven last week when a very large amount of medicines needed to be shipped from Italy to China. Thi...
Peak season is soon here and with that a higher risk of logistics problems as regards cold chain transportation of pharmaceuticals. We have asked Niklas Adamsso...
Envirotainer, the global market leader in secure cold chain solutions for air transport of pharmaceuticals, today announced that they are upgrading their networ...
Envirotainer, the global market leader in secure cold chain solutions for air transport of pharmaceuticals, today announced that they are upgrading their networ...
We offer unbeatable logistics coverage from across the world. We have 50+ service stations globally, covering more than 300 airports, over 2,000 trade lanes, and have regional operations centers in APAC, EMEA, and Americas.
To ensure the safe delivery of pharmaceuticals and to meet the requirements of a more demanding regulatory landscape, we need to acknowledge that training and education plays a vital role in safeguarding temperature-sensitive products during transport.
In this article we present a real-world business case that shows how innovative cold chain solutions can secure transportation at year-end, thereby maximizing long-term profits and improve customer retention for the forwarder.
The pharmaceutical industry has for many years been a prioritized customer for the air freight sector, but the increasing volumes of e-commerce have changed the game, especially at peak season. Now, pharmaceutical companies face the risk of having their products left on the tarmac due to capacity constraints, while handbags and other luxury goods are shipped with higher-yield express delivery instead.
India is the world’s third largest producer of pharmaceuticals in terms of volume. Low costs of manufacturing as well as government subsidies for biosimilars development makes India attractive for export production, with many Western-Indian partnerships, and the demand in the US and Europe is expected to sustain a high growth rate over a longer period.
This website uses cookies to help give you the best experience when you visit. By using this website, you consent to our cookies and privacy policy. Read more
